Roche (Basel) picked up Ventana Medical Systems (Tucson, AZ) in January for approximately $3.4 billion. Roche attempted to buy Genentech (South San Francisco, CA), which rejected the initial offer of $89 per share, or $43.7 billion, in August. Many analysts believe a takeover is inevitable, however, with Roche to offer as much as $100 per share.
Among the other deals this year are Takeda's (Osaka, Japan) $8.9-billion takeover of Millennium Pharmaceuticals (Cambridge, MA). Fresenius (Bad Homburg, Germany) acquired APP Pharmaceuticals (Schaumburg, IL) for $3.7 billion. Sanofi-Aventis (Paris) won over Zentiva's (Prague) board of directors in September with a $2.6-billion bid after its offer of $2.4 billion was rejected. Daiichi Sankyo (Tokyo) purchased a 63.9% stake in Ranbaxy Laboratories (Gurgaon, Haryana, India) for $4.1 billion. Teva's (Jerusalem) $7.5-billion acquisition of Barr (Montvale, NJ) is expected to close by year's end. Expect big acquisitions to continue as companies look for ways to compete with generics while increasing their market share.Alexis Pellek is an assistant editor of Pharmaceutical Technology.